Instructions to Authors

General Policy. IN VIVO is a multidisciplinary journal designed to bring together high quality original works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The focus of the journal is the publication of works on: (a) experimental development and application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; and (c) development and characterization of models for biomedical research. A main aim of IN VIVO is to ensure the prompt publication of accepted articles, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report unpublished original works that are not under consideration for publication by another journal, and that they will not be published again in the same form. On publication of a manuscript in IN VIVO, which is a copyrighted publication, the legal ownership of all published parts of the manuscript passes from the Author(s) to the Journal. All material submitted to IN VIVO will be subject to review, when appropriate, by two members of the Editorial Board. The Editors reserve the right to improve manuscripts in terms of grammar and style. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. The Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society must be followed. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in IN VIVO for public archiving in PubMed Central.

Manuscripts. Two types of papers may be submitted: (i) papers containing completed original work, and (ii) review articles concerning fields of recognizable progress. Papers should be written in clear, concise English. Spelling should follow that of the "Oxford English Dictionary". Ideally, manuscripts should not exceed fourteen (14) pages (approx. 250 words per double-spaced page) corresponding to four (4) printed pages. Papers exceeding four (4) printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work, full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words and an abbreviated running title; (b) Abstract not exceeding 150 words, organized according to the following headings: Background - Materials and Methods or Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods or Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; and (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s preference. Review articles should not exceed 35 pages (approximately 250 words per double-spaced page) including all tables, figures and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, rather than photographic copies. A charge will be made for a colour plate. Figures should be numbered with Arabic numerals and include a short title, and legend if appropriate.

Tables. Each table should be submitted on a separate page, double-spaced. Tables should be numbered with Roman numerals and should include a short title and legend if appropriate.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined on first usage. References. Citations for the reference section of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively in the order that they appear in the text. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. Anticancer Res 1: 205-216, 1981. 2 McGuire WL and Chamness GC: Studies on the oestrogen receptor in breast cancer. In: Receptors for Reproductive Hormones. O'Malley BW and Chamness GC (eds.). New York, Plenum Publ Corp, pp. 113-136, 1973. In the text, references should be denoted as: (1), (2-5), (6, 7) etc.

Submission of Manuscripts. You can send your article via e-mail to journals@iiar-anticancer.org, indicating in which journal you wish to be submitted (ANTICANCER RESEARCH, IN VIVO or CANCER GENOMICS & PROTEOMICS). The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments. OR You can send the manuscript of your article via regular mail in a usb stick, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address: Dr. J.G. Delinassios, International Institute of Anticancer Research (IIAR), Editorial Office of ANTICANCER RESEARCH, IN VIVO and CANCER GENOMICS & PROTEOMICS. 1st km Kandarithiou-Kalamou Road, P.O. Box 22, GR-19014, Kandandriti, Attiki, Greece. Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent by e-mail to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Reprints may be ordered after the acceptance of the paper.

Antiviral Activities of Extracts of Euphorbia hirta L. against HIV-1, HIV-2 and SIVmac251: A. GYURIS, L. SZLÁVÍK, J. MINÁROVITS, A. VASAS, J. MOLNÁR, J. HOHMANN (Budapest; Szeged, Hungary) ........ 429

Clinical Studies

Can We Avoid Inadvertent Parathyroidectomy During Thyroid Surgery? N. SORGATO, G.M. PENNELLI, I. MERANTE BOSCHIN, E. CASAL IDE, C. PAGETTA, A. PIOTTO, A. TONIATO, G.L. DE SALVO, E. HINDIÉ, A. AL-NAHHAS, D. RUBELLO, M.R. PELIZZO (Padova; Rovigo, Italy; Paris, France; London, UK) .......................................................................................................................................................... 433

Peritoneal Carcinomatosis from Ovarian Epithelial Primary: Combined Aggressive Treatment. F. CAVALIERE, D. GIANNARELLI, M. VALLE, O. FEDERICI, G. LIOTTA, P. PERRI, F. DI FILIPPO, A. GAROFALO, P. IALONGO (Rome, Italy) .................................................................................................................. 441

Thoracic Stop-flow Perfusion for Refractory Lymphoma: A Phase I-II Evaluation Trial. C. RUSCITTI, S. GUADAGNI, F. RUSSO, G. PALUMBO, G. FIORENTINI, A. MAMBRINI, M. CANTORE, E. KANAVOS, A. PINTO, G. AMICUCCI (L’Aquila; Naples; Empoli; Carrara, Italy) ................................................................. 447


Successful Treatment of Cryptococcal Meningitis with a Combination of Liposomal Amphotericin B, Flucytosine and Posaconazole: Two Case Reports. V. ESPOSITO, R. VIGLIETTI, M. GARGIULO, R. PARRELLA, M. ONOFRIO, V. SANGIOVANNI, D. AMBROSINO, A. CHIRIANNI (Naples, Italy) ........................................... 465


Use of Rituximab in Combination with Conventional Chemotherapy for the Treatment of Non-Hodgkin’s Lymphoma of the Head and Neck. L. MANOLOPOULOS, I.P. GOMATOS, E. LEANDROS, L. ALEVIZOS, N. GEORGIOU, J. GIOTAKIS, E. FEREKIDIS (Athens, Greece) .................................................................................................................. 475

Assessment of a New Hylauronic Acid Filler. Double-blind, Randomized, Comparative Study between Puragen and Captique in the Treatment of Nasolabial Folds. M. ONESTI, M. TOSCANI, G. CURINGA, S. CHIJUMMARIELLO, N. SCUDERI (Rome, Italy) .................................................................................................................. 479


Abstracts of the First Workshop of the European Association for Predictive, Preventive and Personalised Medicine .................................................................................................................. 491

Errata .................................................................................................................................................. 499

* Review (page 369)